PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection.

Emerging strategies that center upon the mammalian target of rapamycin (mTOR) signaling for neurodegenerative disorders may bring effective treatment for a number of difficult disease entities. Here we show that erythropoietin (EPO), a novel agent for nervous system disorders, prevents apoptotic SH-...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhao Zhong Chong, Yan Chen Shang, Shaohui Wang, Kenneth Maiese
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e4748a24e1de4cf9a68d9afe7be07a80
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e4748a24e1de4cf9a68d9afe7be07a80
record_format	dspace
spelling	oai:doaj.org-article:e4748a24e1de4cf9a68d9afe7be07a802021-11-18T07:05:07ZPRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection.1932-620310.1371/journal.pone.0045456https://doaj.org/article/e4748a24e1de4cf9a68d9afe7be07a802012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23029019/?tool=EBIhttps://doaj.org/toc/1932-6203Emerging strategies that center upon the mammalian target of rapamycin (mTOR) signaling for neurodegenerative disorders may bring effective treatment for a number of difficult disease entities. Here we show that erythropoietin (EPO), a novel agent for nervous system disorders, prevents apoptotic SH-SY5Y cell injury in an oxidative stress model of oxygen-glucose deprivation through phosphatidylinositol-3-kinase (PI 3-K)/protein kinase B (Akt) dependent activation of mTOR signaling and phosphorylation of the downstream pathways of p70 ribosomal S6 kinase (p70S6K), eukaryotic initiation factor 4E-binding protein 1 (4EBP1), and proline rich Akt substrate 40 kDa (PRAS40). PRAS40 is an important regulatory component either alone or in conjunction with EPO signal transduction that can determine cell survival through apoptotic caspase 3 activation. EPO and the PI 3-K/Akt pathways control cell survival and mTOR activity through the inhibitory post-translational phosphorylation of PRAS40 that leads to subcellular binding of PRAS40 to the cytoplasmic docking protein 14-3-3. However, modulation and phosphorylation of PRAS40 is independent of other protective pathways of EPO that involve extracellular signal related kinase (ERK 1/2) and signal transducer and activator of transcription (STAT5). Our studies highlight EPO and PRAS40 signaling in the mTOR pathway as potential therapeutic strategies for development against degenerative disorders that lead to cell demise.Zhao Zhong ChongYan Chen ShangShaohui WangKenneth MaiesePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 9, p e45456 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Zhao Zhong Chong Yan Chen Shang Shaohui Wang Kenneth Maiese PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection.
description	Emerging strategies that center upon the mammalian target of rapamycin (mTOR) signaling for neurodegenerative disorders may bring effective treatment for a number of difficult disease entities. Here we show that erythropoietin (EPO), a novel agent for nervous system disorders, prevents apoptotic SH-SY5Y cell injury in an oxidative stress model of oxygen-glucose deprivation through phosphatidylinositol-3-kinase (PI 3-K)/protein kinase B (Akt) dependent activation of mTOR signaling and phosphorylation of the downstream pathways of p70 ribosomal S6 kinase (p70S6K), eukaryotic initiation factor 4E-binding protein 1 (4EBP1), and proline rich Akt substrate 40 kDa (PRAS40). PRAS40 is an important regulatory component either alone or in conjunction with EPO signal transduction that can determine cell survival through apoptotic caspase 3 activation. EPO and the PI 3-K/Akt pathways control cell survival and mTOR activity through the inhibitory post-translational phosphorylation of PRAS40 that leads to subcellular binding of PRAS40 to the cytoplasmic docking protein 14-3-3. However, modulation and phosphorylation of PRAS40 is independent of other protective pathways of EPO that involve extracellular signal related kinase (ERK 1/2) and signal transducer and activator of transcription (STAT5). Our studies highlight EPO and PRAS40 signaling in the mTOR pathway as potential therapeutic strategies for development against degenerative disorders that lead to cell demise.
format	article
author	Zhao Zhong Chong Yan Chen Shang Shaohui Wang Kenneth Maiese
author_facet	Zhao Zhong Chong Yan Chen Shang Shaohui Wang Kenneth Maiese
author_sort	Zhao Zhong Chong
title	PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection.
title_short	PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection.
title_full	PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection.
title_fullStr	PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection.
title_full_unstemmed	PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection.
title_sort	pras40 is an integral regulatory component of erythropoietin mtor signaling and cytoprotection.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/e4748a24e1de4cf9a68d9afe7be07a80
work_keys_str_mv	AT zhaozhongchong pras40isanintegralregulatorycomponentoferythropoietinmtorsignalingandcytoprotection AT yanchenshang pras40isanintegralregulatorycomponentoferythropoietinmtorsignalingandcytoprotection AT shaohuiwang pras40isanintegralregulatorycomponentoferythropoietinmtorsignalingandcytoprotection AT kennethmaiese pras40isanintegralregulatorycomponentoferythropoietinmtorsignalingandcytoprotection
_version_	1718424011708301312

PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection.

Ejemplares similares